Join Us for Our 2019 Cabin Fever Continuing Educating Program!

Friday March 15, 2019 – Sunday March 17, 2019

North Conway Grand Hotel
72 Common Court North Conway, NH 03860

Friday March 15th
7-9:00pm Welcome Reception, Exhibits and Student Posters

Saturday March 16th
8:00am The 2019 ADA Guidelines for the Treatment of Type 2 Diabetes – A Review of Drug Therapy Recommendations
Jennifer Goldman, PharmD, CDE, BC-ADM, FCCP
9:00am Controversies in Sepsis Management
Alyson Esteves, PharmD, BCPS, BCCCP
5:30pm Dinner
7:00pm C-PEC Selection Considerations and Usage Updates of USP <797> Proposed Revision
Brian Marquis, BSP, R.Ph, RCCP-SCF

Sunday March 17th
8:30-10:30am Resident Clinical Pearls
NH Pharmacy Residents [Sonya Kara, PharmD, Emily Burton, PharmD, Stephanie Brady, PharmD, Emily Marden, PharmD, Stephanie Guay, PharmD, Grant Lee, PharmD, Emily Hillel, PharmD, Marc Fortunga, PharmD, Arlinda Azizolli, PharmD]

To book your hotel accommodations, call: 800-655-1452
When booking your room, be sure to mention you are part of the NHSHP Cabin Fever group!
Group Rate: Fri and Sat $159/night
Saturday only $189

To receive group rates, hotel reservations must be made by February 15, 2019

ACCREDITATION INFORMATION

University of New England, College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program will provide the participant with 5.0 contact hours (0.5 CEUs) of continuing pharmacy education credit for completion of this knowledge-based activity. Attendance and completion of program evaluations are required for statements of credit. Attendees must complete a Program Evaluation Form immediately after each presentation.

Audience: This activity is accredited for pharmacists interested in improving their knowledge in the areas outlined in the agenda.
**PROGRAM OBJECTIVES**

The 2019 ADA Guidelines for the Treatment of Type 2 Diabetes - A Review of Drug Therapy Recommendations
- Identify appropriate strategies to incorporate the ADA 2019 standards of care for the management of hyperglycemia in patients with type 2 diabetes
- Recognize evidence-based treatment options that optimize outcomes in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD), heart failure and chronic kidney disease
- List drug therapy options for patients with type 2 diabetes with consideration to avoiding hypoglycemia and weight gain and minimizing cost
- List the potential cardiovascular and renal benefits and risk of various treatment approaches for diabetes to patients and members of the healthcare team

**Controversies in Sepsis Management**
- Describe differences in the Sepsis 3 definitions to the systemic inflammatory response system (SIRS) criteria
- Discuss the controversy surrounding time frame bundles in sepsis
- Discuss the role of new adjunct therapies in sepsis management

**C-PEC Selection Considerations and Usage Updates of USP <797> Proposed Revision**
- Properly Select a C-PEC for Common Applications
- List Best Practices for Working Within C-PECs
- Relate Proposed 797 Revisions Into Facility Planning

**Resident Clinical Pearls**

**Apixaban to Prevent Venous Thromboembolism in Patients with Cancer:** Discuss the role apixaban may play in oncology patients with a high-risk of developing a venous thromboembolism

**Andexxa:** Recall the primary outcomes of the Andexxa trials

**Penicillin allergies: the stoplight approach:** Discuss the importance of verifying penicillin allergies and the strategies that can be used to clarify these allergies to ensure appropriate antibiotic prescribing

**Salvage MRSA therapy with Ceftaroline and its role in specific patient populations:** Describe the role of Ceftaroline as salvage therapy in specific patient populations

**Methylene blue in ifosfamide induced encephalopathy:** Recognize potential dosing adjustments for doxorubicin and vincristine in renal and hepatic failure

**Peanut allergy and ipratropium:** Discuss the importance of ipratropium use in asthma and analyze the evidence regarding this medication and known peanut allergy

**Hyperinsulinemic-Euglycemic Therapy (HIET) in Calcium Channel Clocker and Beta-Blocker Overdose:** Review a comprehensive approach to HIET in calcium-channel blocker and beta-blocker overdose

**Usage and Roles of Direct Oral Anticoagulant (DOAC) in the Obese Population:** Assess the role of DOACs in the obese population

**Clinical Management of Massive Acetaminophen (APAP) Overdoses:** Describe the clinical presentation and treatment of patients who present with massive APAP overdose

**Registration** (please print)

<table>
<thead>
<tr>
<th>FULL NAME</th>
<th>_______________________________</th>
</tr>
</thead>
<tbody>
<tr>
<td>EMPLOYER</td>
<td>_______________________________</td>
</tr>
<tr>
<td>HOME ADDRESS</td>
<td>________________________________</td>
</tr>
<tr>
<td>CITY</td>
<td>STATE</td>
</tr>
<tr>
<td>TELEPHONE</td>
<td>_______________________________</td>
</tr>
<tr>
<td>E-MAIL ADDRESS</td>
<td>________________________________</td>
</tr>
<tr>
<td>NABP #</td>
<td>DOB (MM/DD)</td>
</tr>
</tbody>
</table>

**REGISTRATION FEES***

- $110 Members
- $185 Non Members (includes 2019 membership)
- $50 Students
- $75 Adult guest (no CE)
- $35 Child (< 12 yrs) guest

I plan to attend:
- Friday evening reception □ Yes □ No
- Saturday evening dinner □ Yes □ No

Please indicate total enclosed $___________

Registrations must be received by March 4, 2019

*Registration includes breakfast Saturday & Sunday, Friday evening reception, Saturday dinner and 5 hours of ACPE credit, including 2 hrs of law!

To Register: Enclose completed form with a check payable to NHSHP – OR – register online at www.NHSHP.org

**Program Cancellation Policy**

Please email Kristine Willett on or before March 2, 2018 for cancellations and refunds. All refunds are subject to a $10 processing fee. No refunds after March 5, 2018.

Kristine.Willett@mcphs.edu

We will have a SILENT AUCTION throughout the weekend to benefit Student Scholarships.